Relationship of Notch1 expression with sensitivity of breast cancer to paclitaxel

Li Zhao, Jiao Zhang, Li Fu, Yongjie Ma, Feng Gu

    Research output: Contribution to journalArticle

    Abstract

    Objective: To observe the association between Notchl expression and PAC sensitivity in breast cancer cells. Methods: The siRNA interference against Notch1 and endocellular Notch1 inhibitor, N-[N-(3,5-difluorophenacetyl)-1- alanyl]-S-phenylglycine t-butyl lester (DAPT) were employed to down-regulate Notch1 activity and the inhibitory action was detected through Western blot and RT-PCR, respectively. After 24 hours of exposure to PAC at different concentrations (0, 1, 5, 10, 15, 20, 25 μg/mL), the cell viability of the control group and the experimental group was tested using the MTT colorimetric method, i.e., [3-(4,5)-dimethylthiahiazo(-z-yl)-3,5-di-phenytetrazoliumromide]). Immunohistochemistry (IHC) was used to observe the Notchl expression in PAC-sensitive and non-sensitive cases, and collagen gel droplet embedded culture-drug sensitivity test (CD-DST) was carried out to determine the sensitivity of different cases to the PAC. Results: Down-regulation of Notch1 expression by Notch1 siRNA interference or inhibition of Notch1 activity by DAPT significantly increased the sensitivity of MDA-MB-231 cells to PAC (P < 0.05). In the IHC study, the Notch1 expression in PAC-sensitive cases was much lower than in non-sensitive cases (P < 0.01). Conclusion: The Notch1 expression significantly influences and negatively correlates with the sensitivity of breast cancer to PAC.

    Original languageEnglish (US)
    Pages (from-to)547-550
    Number of pages4
    JournalChinese Journal of Clinical Oncology
    Volume39
    Issue number9
    DOIs
    StatePublished - May 15 2012

    Keywords

    • Breast cancer
    • Notch1
    • Paclitaxel (PAC)
    • Sensitivity

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Relationship of Notch1 expression with sensitivity of breast cancer to paclitaxel'. Together they form a unique fingerprint.

  • Cite this